Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 1999

View Archived Issues

U.S. patent granted for conjugate vaccine against group B streptococci

Nortran and Roche terminate arrhythmia collaboration

BioChem Pharma moves towards integration, buys back shares from Glaxo Wellcome

Solvay to acquire Unimed

Novopharm Biotech's fully human antibody vaccine enters clinical trials

Medco's imaging adjunct completes phase I trial

Intrathecal morphine administration via implantable pump in the treatment of chronic pain

European hypertension news: efficacy of beta-blocker talinolol in hypertensive patients

Hepatoprotective agents in development at Korean labs

Cerebrus presents dual antioxidant/iron-chelating agents for stroke

RPR research group prepares new cell adhesion inhibitors especially useful in asthma

Mechanism of action of AGN-192403 determined in rabbit model

New tyrosine kinase inhibitor series presented by Pfizer

Search for new anticonvulsants with affinity for novel binding site continues at SB

BioCryst reports progress in the search for novel flu treatments

New series from American Home Products elevates HDL cholesterol

Two research teams reach the same conclusion: topiramate is a promising antimigraine agent

Fujisawa develops antiinflammatory agents acting on cyclooxygenase

Pfizer's new substance P antagonists particularly useful as antiemetics

Selective M1 receptor agonist chosen for further study under Novo Nordisk/Lilly collaboration

Stable immunomodulators related to Imreg-1 developed at BioChem Pharma

Botox is not effective in treating whiplash injury

Chiroscience completes worldwide marketing agreements for Chirocaine

Safety and pharmacokinetic data presented for almotriptan at Boston headache meeting

News from ENDO '99: Sensus's treatment for acromegaly excels in phase II and III trials

Campylobacter vaccine completes phase II trial

Pericranial botulinum toxin assessed in various types of migraine

Active Biotech and Oxigene enter inflammatory disease collaboration

Transdermal testosterone as a treatment for female sexual dysfunction

Phase II results of Fibrimage presented at Society of Nuclear Medicine meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...